Dibya Sarathi

Scientist at Biocon Limited | Utkal University | API R&D Downstream and Peptides.

Role: Scientist at Biocon
Location: Bengaluru, KA, IN
LinkedIn followers: 500 followers

About Dibya Sarathi

I am Dibya Sarathi, A Peptide chemist with diversified knowledge in synthesis of Peptide. √ Synthesis and process development of Peptide Derived APIs and the related Impurities by Solid Phase Peptide Synthesis. √ Characterization of Impurities by different analytical methods (HPLC, UPLC, LCMS, HRMS NMR) √ Hands on experience in Automated Peptide Synthesizer (CS Bio) and Microwave Peptide Synthesizer (Liberty Blue). √ Have experience in Feasibility Check, Process Development and Optimization, Process Validation, Vendor Qualifications. √ Participation in Scale Up activities (Plant batch ) and technology transfer upto commercial level following GMP protocols. √ Participate in CIP (Cost improvement program) of the project.

Experience

Scientist
Biocon
Jul 2024 — Present · Bengaluru, IN

Contact information

Verified work emails, personal emails, and direct dials — unlocked in one click.

Work email
•••••@biocon.com
Personal email
•••••@•••••.com
Direct dial
+•• ••• ••• ••••

Unlock verified contacts

Free to start · No credit card required

Current company

Biocon

Biotechnology Research · 12K employees · Bangalore, Karnataka, India

Fraudulent Recruitment Advisory: Biocon and its subsidiaries never charge candidates any fee at any stage of recruitment. Learn how to identify and report fraudulent job offers: https://www.biocon.com/fraudulent-recruitment-advisory/ Biocon Limited (BSE: 532523, NSE: BIOCON) is a global biopharmaceutical company driven by its purpose to provide affordable, life-changing medicines to patients worldwide. Headquartered in Bengaluru, India, Biocon addresses some of the world’s most pressing healthcare challenges across chronic and non-communicable diseases by offering both biosimilars and generics at scale across geographies. Through this diversified portfolio, Biocon focuses on areas of high unmet need, spanning key therapy areas including diabetes, oncology, obesity, cardiovascular diseases, immunology, ophthalmology, and bone health. The Company has pioneered several industry firsts that have helped shape the global biosimilars landscape. To date, the company has commercialized 12 biosimilar products and 30+ generic formulations globally. It has robust research and development pipeline of 20+ biosimilar assets, as well as GLP-1 peptides and other complex generics. With an integrated lab-to-patient model, Biocon brings together research and development, manufacturing, and commercial capabilities to ensure reliable and scalable supply of medicines. The company operates in more than 120 countries, supported by seven manufacturing sites, three R&D sites, 18 offices worldwide, and a workforce of over 9,500 employees. Biocon has been included in the S&P Global Sustainability Yearbook 2026 for the fourth consecutive year, underscoring its commitment to sustainable and responsible growth.

biocon.com

Find verified contacts for anyone on LinkedIn

Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.

Start for free See how it works

Free plan included · No credit card required

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.